Brian M. Culley

CIK: 0001310683

Transaction Breakdown

Open Market Buys (P)2 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (20.0%)

Derivative conversions

Awards (A)3 (30.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (30.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LCTX

Lineage Cell Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

LCTX
Lineage Cell Therapeutics, Inc.
Mar 12, 2026
Purchase(P)
Direct
15K shares at avg. $1.63$24K
LCTX
Lineage Cell Therapeutics, Inc.
Mar 5, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
3.3M shares-
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2026
Tax Payment(F)
Direct
12.9K shares at avg. $1.80$23K
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2026
Exercise(M)
Direct
31.3K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Dec 19, 2025
Tax Payment(F)
Direct
334 shares at avg. $1.68$561.12
LCTX
Lineage Cell Therapeutics, Inc.
Dec 19, 2025
Award(A)
Direct
8.9K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Mar 10, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
2.3M shares-
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2025
Exercise(M)
Direct
31.2K shares-
LCTX
Lineage Cell Therapeutics, Inc.
Feb 11, 2025
Tax Payment(F)
Direct
12.5K shares at avg. $0.65$8K
LCTX
Lineage Cell Therapeutics, Inc.
Nov 21, 2024
Purchase(P)
Direct
40K shares at avg. $0.60$24K

		Type	Shares	Price		Ownership
Mar 12, 2026	LCTX Lineage Cell Therapeutics, Inc.	Purchase(P)	15,000	$1.63	$24,375	Direct
Mar 5, 2026	LCTX Lineage Cell Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	3,250,000	-	-	Direct
Feb 11, 2026	LCTX Lineage Cell Therapeutics, Inc.	Tax Payment(F)	12,869	$1.80	$23,164	Direct
Feb 11, 2026	LCTX Lineage Cell Therapeutics, Inc.	Exercise(M)	31,250	-	$0	Direct
Dec 19, 2025	LCTX Lineage Cell Therapeutics, Inc.	Tax Payment(F)	334	$1.68	$561	Direct
Dec 19, 2025	LCTX Lineage Cell Therapeutics, Inc.	Award(A)	8,925	-	-	Direct
Mar 10, 2025	LCTX Lineage Cell Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	2,300,000	-	-	Direct
Feb 11, 2025	LCTX Lineage Cell Therapeutics, Inc.	Exercise(M)	31,249	-	-	Direct
Feb 11, 2025	LCTX Lineage Cell Therapeutics, Inc.	Tax Payment(F)	12,547	$0.65	$8,156	Direct
Nov 21, 2024	LCTX Lineage Cell Therapeutics, Inc.	Purchase(P)	40,000	$0.60	$24,000	Direct

1-10 of 10 transactions

About Culley Brian M

Culley Brian M (SEC CIK 0001310683) files insider reports with the SEC as President and CEO of Lineage Cell Therapeutics, Inc. (LCTX).

Signal8 holds 7 ownership filings by Culley Brian M, all Form 4s, filed between Nov 22, 2024 and Mar 12, 2026. Those filings report 10 transactions, from Nov 21, 2024 to Mar 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Culley Brian M's filings is in CARLSBAD, CA.

Recent filings by Culley Brian M

Mar 12, 2026: Open-market purchase of LCTX shares (Form 4, code P).
Mar 5, 2026: Grant or award of LCTX derivative securities (Form 4, code A).
Feb 11, 2026: Tax withholding of LCTX shares (Form 4, code F).
Feb 11, 2026: Option exercise of LCTX shares (Form 4, code M).
Dec 19, 2025: Tax withholding of LCTX shares (Form 4, code F).

Other insiders filing for Lineage Cell Therapeutics, Inc. (LCTX)

Bradsher Neal C, Director
Jayasuriya Anula, Director
Mulroy Michael H., Director
ANDREWS DEBORAH J, Director
Russell Angus C., Director
Amin Dipti, Director

How to read Form 4 transaction codes